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Coronavirus disease 2019 (COVID-19) is escalating all over the world and has higher 
morbidities and mortalities in certain vulnerable populations.  People Who Use Drugs (PWUD) 
are a marginalized and stigmatized group with weaker immunity responses, vulnerability to 
stress, poor health conditions, high-risk behaviors, and lower access to health care services. 
These conditions put them at a higher risk of COVID-19 infection and its complications. In this 
paper, an international group of experts on addiction medicine, infectious diseases, and disaster 
psychiatry explore the possible raised concerns in this issue and provide recommendations to 
manage the comorbidity of COVID-19 and Substance Use Disorder (SUD). 
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1. Introduction
oronavirus Disease 2019 (COVID-19) is 
a new member of the coronavirus family 
that infect humans (Zhu et al., 2020). It first 
emerged in the Wuhan region of China in 
November 2019 (Lai Shih, Ko, Tang, & 
Hsueh, 2020). By March 2020, the World 
Health Organization (WHO) assessed the 
global situation of COVID-19 as a pandemic. Patients 
with cardiovascular diseases, chronic respiratory diseas-
es, people aged 60 or older, and males have a higher risk 
of mortality than the rest of the population (Chen et al., 
2020; Huang et al., 2020; Wang et al., 2020).
Frequently reported clinical symptoms at the onset of 
the disease include pyrexia (83%-98%), cough (46%-
82%), myalgia or fatigue (11%-44%), and shortness of 
breath (31%) (Chen et al., 2020; Huang et al., 2020; 
Wang et al., 2020). Sore throat and, less commonly, 
sputum production, headache, hemoptysis, and diarrhea 
have also been reported (Chan et al., 2020). In more se-
vere cases, COVID-19 can cause pneumonia, severe and 
acute respiratory syndrome, and sometimes (1%-3% of 
all infected cases) death (World Health Organization, 
2020b). Currently, the medications used for severe cas-
es of COVID-19 include chloroquine phosphate (Gao, 
Tian, & Yang, 2020), hydroxychloroquine sulfate (Ja-
vadi et al., 2006), lopinavir/ritonavir (Li & De Clercq, 
2020; Lim et al., 2020), oseltamivir (Li & De Clercq, 
2020; Vetter, Eckerle, & Kaiser, 2020), and ribavirin (Li 
& De Clercq, 2020). but none have been approved by 
regulatory authorities for use against COVID-19.
The most common strategies, as advised by WHO, 
include preventative measures such as quarantine and 
limitations of movement in infected areas (Hellewell et 
al., 2020; Wu, Leung,  & Leung, 2020), interruption of 
human-to-human transmission, early identification and 
isolation, providing appropriate care for patients, identi-
fying and reducing transmission from the animal source, 
and minimizing the social and economic impact through 
Highlights 
● Health care providers in treatment and harm reduction settings must always have PPE.
● Screening of PWUD with COVID-19 is a priority with respects to human rights.
● Creative, evidence based and realistic approaches are needed for the current situation.
● Virtual context and mobile base platforms could  facilitate mainstream interventions.
● Different clinical manifestations and drug interactions are major issues in PWUD with COVID19.
Plain Language Summary 
The new coronavirus created a complex situation for all sections of the communities around the world. Health care 
providers are in the frontline of intervening to stop the spread of COVID-19. Meantime people who use drugs (PWUD) 
are at increased risk during this pandemic since they are a stigmatized and marginalized populations. Health service 
providers who are providing different needs for PWUD in treatment and/or harm reduction settings should always 
keep themselves safe with using standard PPE based on the WHO recommendations. Additionally PWUDs live in 
crowded locations and so screening and early identification of COVID-19 patients are important to break the cycle 
of transmission. It is recommended that protocols for opioid substitution therapy modify with complete adherence to 
patients' safety regarding both opioid drug risks and COVID-19 infections. It is important to have in mind that different 
stages of OST needs different approaches. PWUDs are more vulnerable to stress and other mental health problems. 
This makes psychological interventions such as cognitive-behavioral therapy and other modalities very important to 
have for PWUDs during these difficult and challenging times to assist and sustain treatment. Medical conditions such 
as respiratory illness, renal insufficiency, chronic pain and cardiovascular disorders are also important medical condi-
tions that should be addressed appropriately among PWUDs with COVID-19. Health service providers in both fields 
of addiction treatment and COVID-19 treatment and prevention systems should be aware regarding special situations 
arising in the overlap of drug use and COVID-19 illness. 
C
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multispectral partnerships (World Health Organization, 
2020a). Bai and colleagues mentioned some COVID-19 
transmission from asymptomatic patients as a challenge 
for preventive activities (Bai et al., 2020).
In most countries, People Who Use Drugs (PWUD) 
are stigmatized and marginalized population with lower 
access to healthcare. They suffer from poorer health, 
weaker immune function, chronic infections, various 
issues with respiratory, cardiovascular, and metabolic 
systems, as well as a range of psychiatric comorbidities 
(Ahern, Stuber, & Galea, 2007; Stuber, Galea, Ahern, 
Blaney, & Fuller, 2003). PWUD are a marginalized 
group who experience high rates of morbidities, three 
to five times higher compared to the general population 
(O’Connell, 2004). Cheung et al. estimated that the risk 
of death among young PWUD homeless women in To-
ronto is 5 to 30 times higher than their housed counter-
parts (Bohnert & Ilgen, 2019; Fernandez-Quintana et al., 
2019). Substance use imposes different health problems, 
which may complicate superimposed infection with CO-
VID-19. For instance, chronic high alcohol consump-
tion significantly increases the risk of acute respiratory 
distress syndrome (McCarthy et al., 2020). During the 
2009 H1N1 epidemic, a history of opium inhalation had 
been identified as a risk factor for admission to an In-
tensive Care Unit (ICU) with confirmed H1N1 (Tabarsi 
et al., 2011). Additionally, it is essential to understand 
how PWUD differently perceive danger and risk-taking 
behaviors during an epidemic, making them more risk 
averse (Manfredi & D’Onofrio, 2013; Rhodes, 1997). 
PWUD have a higher rate of smoking and different 
studies estimated the current smoking rate of more than 
70% among them (Duan et al., 2017; Sutherland et al., 
2016; Weinberger, Gbedemah, & Goodwin, 2017). Sev-
eral studies found smoking a significant risk factor for 
Middle East Respiratory Syndrome (MERS) transmis-
sion (Alraddadi et al., 2016; Nam, Park, Ki, Yeon, Kim, 
& Kim, 2017; Sherbini Iskandrani, Kharaba,  Khalid, 
Abduljawad, & Hamdan, 2017).
A literature review did not reveal even one article focus-
ing on Substance Use Disorder (SUD) and COVID-19. 
Therefore, a group of international experts on addiction 
medicine, infectious diseases, and disaster management 
teamed up to explore the comorbidity of COVID-19 in-
fection with substance use disorder and identify the nec-
essary recommendations for health service providers and 
policymakers in this situation. 
1.1. The system
Although the majority of COVID-19 infections are 
mild, the number of severe cases in a pandemic has the 
potential to overwhelm any healthcare system. Conse-
quently, health authorities may be required to repurpose 
health services and facilities away from PWUD. When 
such an incident occurs, a business continuity protocol 
will cover several contingency measures so that organiza-
tions supporting PWUD will continue to provide their es-
sential services. A response to both COVID-19 and drug 
use involves government, different sectors of the com-
munity and health authorities (WHO Director-General’s 
opening remarks at the media briefing on COVID-19 on 
March 5, 2020) to implement evidence-based prevention 
programs as well as engaging different stakeholders for 
policy coordination (Volkow, Poznyak, Saxena,  Gerra, 
& UNODC‐WHO Informal International Scientific Net-
work, 2017). Generally, drug use prohibition and crimi-
nalization approaches result in higher stigmatization and 
discrimination against PWUD (Boyd & MacPherson, 
Vancouver Area Network of Drug Users, 2018; Santos 
da Silveira, Andrade de Tostes, Wan, Ronzani, & Corri-
gan, 2018). This approach puts PWUD at a higher risk of 
viral transmission. Governments, health authorities, and 
other relevant stakeholders should identify the provision 
of services for PWUD as essential services to support a 
comprehensive and proactive response to the challenges 
that COVID19 places on this population, especially when 
they are under treatment (Ekhtiari et al., 2019).
1.2. The PWUD population
PWUD have poor access to health services due to stig-
ma and discrimination (Ahern, Stuber, & Galea, 2007; 
Salamat, Hegarty, & Patton, 2019). They are among the 
pervasive hard-to-reach populations. For example, stud-
ies show that drug use is one of the significant barriers to 
taking the influenza vaccine (Bryant et al., 2006; Kong, 
Chu, & Giles, 2020). Many homeless PWUD communi-
ties live in crowded groups in shelters and or shooting 
galleries with no or minimal air conditioning facilities. 
Additionally, poor hygiene, risky behaviors such as 
sharing drug-using paraphernalia and intoxication put 
PWUD at higher risk of COVID-19 infection. 
One of the other risk factors for PWUD and People 
Who Inject Drugs (PWID) is their weaker immune sys-
tem due to a range of factors. These factors include 
long-term/high-dose administration of opioid drugs 
(Liang, Liu, Chen, Ji, & Li, 2016; Sacerdote, Franchi, 
Gerra, Leccese, Panerai,  & Somaini, 2008), malnutri-
tion (Haber, Demirkol,  Lange, & Murnion, 2009; Vila et 
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al., 2019), homelessness  (Haber et al., 2009), and long-
term alcohol and methamphetamine use (Nelson, Zhang, 
Bagby,  Happel,  & Raasch, 2008; Radfar & Rawson, 
2014; Roy et al., 2011). Despite lacking evidence for in-
troducing HIV as a risk factor for COVID-19 (British 
HIV Association, 2020), there are some concerns regard-
ing the access to treatment services for People Living 
With HIV/AIDS (PLWHA) and their adherence to an-
tiretroviral therapy (Dadkha, Mohammadi, & Mozafari, 
2008). This situation could finally increase the rate of 
mortality among PLWHA. On the other hand, respira-
tory infections among PWUD are common and, in many 
cases, do not present with recognized symptoms of these 
diseases (Dimassi & Rushton, 2009; Bradley Drum-
mond et al., 2011;  Gordon & Lowy, 2005). Tuberculo-
sis is another respiratory infection that is more common 
among PWUD (Perlman, Salomon,  Perkins,  Yancovitz, 
Paone,  & Jarlais, 1995) even in high-income countries 
(de Vries et al., 2017; Heuvelings et al., 2017). 
1.3. The PWUD care provider
Care providers are at the front line of any outbreak 
response. They are not only at the risk of infection but 
are also prone to burnout and psychological distress. In 
a study conducted on frontline staff involved in the Se-
vere Acute Respiratory Syndrome (SARS) epidemic, it 
was found that they had high levels of burnout, psycho-
logical distress, and posttraumatic stress (Maunder et al., 
2006). This situation is compounded with evidence that 
counselors and therapists for PWUD are well-known as 
having a higher rate of burnout (Vilardaga et al., 2011) 
during usual practice. Staff working in harm reduction 
settings, where most of the health service providers are 
peer groups, should be adequately supported. This sup-
port should prevent cross-viral exposure, psychological 
distress (Hashemian et al., 2015; Lancee, Maunder, & 
Goldbloom, 2008), psychiatric disorders (Tang, Pan, 
Yuan, & Zha, 2017; Zhu et al., 2020), discrimination 
(Gilchrist et al., 2011), and physical and psychological 
violence (World Health Organization, 2020b). Concerns 
regarding infection and the above mentioned stress-
ful events may affect their effectiveness in an outbreak 
(Abolfotouh, AlQarni, Al-Ghamdi, Salam,  Al-Assiri, & 
Balkh, 2017). All staff should have access to Personal 
Protection Equipment (PPE). 
They should perform hand hygiene frequently, use 
alcohol-based hand rub/gels if their hands are not vis-
ibly soiled or with soap and water when they are visibly 
soiled. They must keep at least one meter distance from 
affected individuals, wear a medical mask when in the 
same room with an affected individual, and dispose of 
the material immediately after use. They should clean 
their hands immediately after contact with respiratory 
secretions, cover the nose and mouth with a flexed el-
bow or disposable tissue when coughing and sneezing, 
and refrain from touching eyes, nose, or mouth with po-
tentially contaminated hands (World Health Organiza-
tion, 2020b). Also, they must avoid close contact with 
anyone that has fever or cough (World Health Organiza-
tion, 2020b) and finally improve airflow in living space 
by opening windows as much as possible (World Health 
Organization, 2020b). Self-isolation of individual staff is 
paramount if there are signs of an infection (Heymann & 
Shindo, 2020; World Health Organization, 2020a).
PWUD staff still need to retain their crucial role at a dis-
tance either through digital technology or phone and con-
tinue their PWUD management and treatment plan, such as 
the provision of daily OST medication (Tschakovsky, 2009). 
There is no convincing evidence that the parapherna-
lia and devices for drug use are the primary sources of 
virus transmissions in the latest epidemics of coronavi-
ruses (Alagaili, Briese, Amor,  Mohammed, & Lipkin, 
2019). However, as the main source of viral transmission 
has been defined to occur through the droplets, it makes 
sense to advise PWUD populations to avoid sharing 
cigarettes, pipes (Radfar & Rawson, 2014), water pipes 
and hookahs, and so on (Knishkowy & Amitai, 2005; 
Munckhof, Konstantinos, Wamsley, Mortlock, & Gilpi, 
2003). One should continue providing clean needle and 
syringes and ‘Take-Home’ Naloxone (THN) when ap-
propriate.
2. Early Detection and Referral Systems and 
Linkages to Other Community-based Ser-
vices 
Infected patients are most virulent during the prodro-
mal period. In the case of being mobile and carrying on 
usual activities, they play an essential part in spreading 
the infection to the other parts of the community (Hey-
mann & Shindo, 2020). In such conditions, it is impera-
tive to have an effective mechanism for the active and 
rapid detection of signs and symptoms and patient’s iso-
lation (Hellewell et al., 2020; Shamaei et al., 2009).
During the H1N1 pandemic in 2009, one of the risk 
factors for death or admission at intensive care units was 
a delay in diagnosis (Tabarsi et al., 2011). Early detec-
tion in PWUD can be difficult as COVID-19 symptoms 
could be confused with a withdrawal syndrome (Dimas-
si & Rushton, 2009; Bradley Drummond et al., 2011; 
Gordon & Lowy, 2005). It is highly recommended that 
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a mechanism be implemented for the frequent screen-
ing of COVID-19 in PWUD within harm reduction and 
treatment settings (Salamat, Hegarty, & Patton, 2019; 
Van Olphen, Eliason,  Freudenberg, & Barnes, 2009).
3. Specific Concerns Around Opioid Substi-
tution Therapy
Any pandemic affects illicit drug distribution networks 
(Rahimi Movaghar, Farhoudian,  Rad Goodarzi,  Sharifi, 
Yunesian, & Mohammadi, 2006). Sometimes this situ-
ation persuades PWUD to seek treatment services for 
help, but usually, they switch to a more hazardous con-
sumption. The Iranian COVID pandemic generated the 
highest incidence of mortality secondary to methanol 
toxicity (At least 44 dead from drinking toxic alcohol in 
Iran after coronavirus cure rumor, 2020; Tainted alcohol 
claims more lives than coronavirus in Khuzestan Prov-
ince, Iran, 2020). However, opioid substitution therapy 
(OST) provision of controlled medication has become 
the main focus of the continuity plans around PWUD to 
make sure that such provision is not interrupted during 
the COVID-19 lockdown strategies (being imposed by 
several governments).
3.1 Protocol for opioid pharmacotherapy provision
3.1.1. Prescribing and dispensing of methadone 
and buprenorphine  
Any close personal contact may be harmful and risky 
for COVID-19 transmission. Methadone syrup and bu-
prenorphine tablets or film are often provided to PWUD 
after bringing out their blister packs. Despite no evidence, 
this action might increase the chance of viral transmis-
sion by exposing both staff and PWUD. It is recommend-
ed that dispensing clinics be trained to handle the process 
of tablet delivery with minimum hand contact.
Take-home doses of medications can be provided for 
more extended periods in situations of quarantine, self-
isolation, or lockdown and health service disruptions. 
The maximum time for take-home doses of drugs is rec-
ommended when the dose and social situation are stable. 
Treatment seeking individuals should be adequately 
informed about the changes in the practice, and they 
should receive appropriate support in case of uncertainty 
and concerns. However, decisions should be taken on a 
case by case basis. In summary, individuals under Bu-
prenorphine Maintenance Treatment (BMT) can receive 
accelerated take-home doses after two weeks of initia-
tion. In particular, the people can receive this protocol 
who are at least on 60 mg methadone or 8 mg daily bu-
prenorphine and have no signs of withdrawal symptoms, 
do not experience craving (Mokri, Ekhtiari,  Edalati, & 
Ganjgahi, 2008), are abstinent based on self-reporting, 
and provide negative toxicological tests. This condition 
should be reviewed every 14 days if the individuals pro-
vided with take-home doses are not showing the stability 
mentioned above. Buprenorphine take-home doses are 
probably safer than methadone take-home doses. If the 
person is in isolation and unable to pick up their medica-
tion personally, it can be delivered to their homes, or they 
can authorize someone else to collect the medication.
3.1.2. Optimal medical interventions for new patients
 Opioid Substitution Therapy (OST) is among a category 
of treatment modalities that is normally considered to 
need regular and frequent supervision of patients, espe-
cially early in treatment. It is recommended that a more 
flexible OST program needs to be taken into account 
during the COVID pandemic (Blake & Lyons, 2016). 
Given the safety profile of buprenorphine, it would seem 
to be the preferred substitution treatment for individu-
als who want to initiate treatments. It is faster and safer 
(Maremmani & Gerra, 2010) to reach an effective main-
tenance dose of buprenorphine compared  to methadone, 
in fact it can be done on the first day of treatment. Some 
of the medications under consideration for the treatment 
of COVID-19 can significantly inhibit and/or stimulate 
methadone metabolism, puting patients at the risk of 
withdrawal or toxicity  (Lüthi, Huttner, Speck, & Muelle, 
2007; Winton & Twilla, 2013). Methadone specifically 
in high doses may prolong QT interval and cause fatal 
arrhythmias (Krantz, Lewkowiez, Hays, Woodroffe, 
Robertson, & Mehle, 2002). Possible cardiomyopathy in 
infected patients may increase the chance of Torsade’s 
de Pointes arrhythmia (Lüthi et al., 2007) and, particu-
larly if combined with chloroquine which also prolongs 
the QT interval.
Withdrawal symptoms from buprenorphine are milder 
than that of methadone in case of interruption to the sup-
ply of medication, at least in the short term.
Where available, the long acting (monthly) subcutane-
ous injections are an alternative to providing take home 
doses. Even transdermal buprenorphine should be con-
sidered where no other alternatives exist. Multiple patch-
es can be given simultaneously if necessary to achieve a 
therapeutic dose for opioid dependence treatment.
Additionally, benzodiazepine prescription for myalgia 
or stressful circumstances due to COVID-19 may also 
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increase the risk of toxicity during methadone mainte-
nance treatment (MMT). During the pandemic period, 
it is more likely that individuals with drug use disorders 
or those who are in treatment seek out benzodiazepines 
or other tranquillizers (Dorn, Yzermans, & van der Zee, 
2007; Fassaert et al., 2007). Benzodiazepines misuse 
may mask signs and symptoms of COVID-19 infection 
and could escalate respiratory distress.
3.2. Considerations regarding different stages of 
maintenance therapy
3.2.1. Stage 1: Early stabilization
Patients are at a higher risk of methadone overdose in 
the initial stabilization period of methadone prescription 
(Cornish, Macleod,  Strang,  Vickerman,  & Hickman, 
2010; Degenhardt, Randall, Hall, Law, Butler, & Burns, 
2009). For MMT patients, the authors do not recom-
mend relaxing the methadone dose protocol at this phase 
of treatment however they do suggest avoiding unneces-
sary visits and rigor, on a case by case basis. If acceler-
ated induction is necessary, an additional dose of 30-40 
mg can be followed by a further dose if someone has 
been observed 2 hours after their initial methadone dose. 
If they are still experiencing withdrawal at this time, they 
can safely be given a further dose. For buprenorphine, 
individuals can be rapidly inducted to optimal mainte-
nance doses (16-24 mg daily). 
3.2.2. Stage 2: Late stabilization
Clinicians should consider increasing the dose if the 
individuals are still experiencing daily cravings, ongo-
ing opioid use, or opioid withdrawal. However, clini-
cians should be sensitized in the differentiation between 
withdrawal syndromes, including myalgia, insomnia, 
sweating, fatigue, and nausea with signs and symptoms 
of viral COVID-19 infection. Pupil size is the best guide 
to distinguish opioid withdrawal from the symptoms of 
COVID-19 as this infection does not affect pupil size. 
It should be possible to see pupil size even with video 
consultations.
3.2.3. Stage 3: Maintenance
Although the prescription period of anti-viral treat-
ment is usually less than two weeks and the induction of 
hepatic metabolic enzymes takes more than the regular 
time for Antiretroviral Therapy (ART) prescription, the 
clinicians should be careful about the changes of metha-
done level in these patients during and more specifically 
after termination or discharge of the treatment for CO-
VID-19. Change from split doses to multiple daily doses 
is a strategy in patients who receive antiviral therapy. 
As a result of the induction of methadone metabolism, 
some patients may need a mild increase in their previous 
methadone dosage after a few days of initiating antiviral 
treatment. For buprenorphine, double doses can be given 
every other day for people who are not considered safe to 
receive take-home doses.
3.2.4. Stage 4: Termination
In exceptional situations, some patients on MMT or 
BMT fulfill the criteria for completion of their OST. Ter-
mination is a stressful process (Berger & Smith, 1978) 
and needs close supervision and constant consultation. 
Besides, the emotional distress associated with opioid 
withdrawal may increase the risk of suicidal ideation. 
Termination of MMT and BMT increases the stress, so 
more attendance at treatment centers are needed, and it is 
not recommended during the COVID-19 epidemic.
3.2.5. Detoxification
Some people who use opioids may wish to cease their 
opioid use during the outbreak, either due to reduced 
availability of opioids or the difficulty accessing treat-
ment services. The most straightforward approach to 
detoxification, if available, would be single high dose 
buprenorphine. Doses ranging from 32 to 96 mg have 
been used for this purpose (Ahmadi, Jahromi, Ghahre-
mani,  & London, 2018). Alternative approaches include 
clonidine or a combination of symptomatic medications 
(World Health Organization, 2009).
3.3. Urine/Saliva drug testing 
Individuals with moderate to severe signs of COV-
ID-19 infection need medications consisting of a cock-
tail of ART, antimicrobials, and analgesics. These medi-
cations may interfere with urine or saliva test results. For 
instance, quinolones (e.g. moxifloxacin, lomefloxacin, 
norfloxacin, ofloxacin, ciprofloxacin), rifampin, tolme-
tin (a non-steroidal anti-inflammatory drug) may yield 
a false-positive result in opiates urine drug screening 
(Reisfield, Goldberger, & Bertholf, 2009). Chloroquine 
(Lora-Tamayo, Tena, Rodriguez, & Moren, 2002) may 
result in amphetamine- false-positive urine drug screens. 
Ibuprofen, naproxen, and efavirenz (antiretroviral medi-
cation used to treat and prevent HIV/AIDS) may result 
in false positive in Δ9-Tetrahydrocannabinol (THC) and 
benzodiazepines screening tests (Blank, Hellstern, Schus-
ter, Hartmann,  Matthée, Burhenne, 2009; Rossi, Yaksh, 
Bentley, van den Brande,  Grant,  & Ellis, 2006; Sait-
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man Park, & Fitzgerald, 2014). During the COVID-19 
pandemic, the clinicians should assess the benefits of 
the urinary or saliva testing at this critical circumstance, 
especially as this will potentially increase unnecessary 
risks due to close contacts. 
4. Psychological Consequences
In this pandemic, it seems that information is spreading 
more extensively and rapidly in comparison to the SARS 
outbreak in 2003. However, this condition may result in 
a worsening of public fear, panic, and distress. Social 
isolation may also make individuals susceptible to more 
psychological distress. Consequent economic depres-
sion after a pandemic also causes uncertainty and threats 
to future welfare (Strong, 1990). The unpredictable fu-
ture is exacerbated by myths and misinformation that are 
often driven by fake news and public misunderstanding 
(Bao, Sun,  Meng, Shi, & Lu, 2020). Some patients will 
experience grief over the loss of loved ones.
The relationship between adverse life events and brain 
stress systems have a prominent role in addiction disease 
(Koob, 2008, 2009, 2013). PWUD are much more vul-
nerable to stress and crisis followed by lapse and relapse 
to ex-drug users (Goeders, 2003; Koob et al., 2014; Mili-
vojevic & Sinha, 2018; Somaini et al., 2012). As a result 
of stressful events and disasters, mental health problems 
emerge or exacerbate (Farhoudian, Hajebi, Bahramne-
jad, & Katz, 2013; Farhoudian, Rahimi Movaghar, Rad 
Goodarzi,  Younesian,  & Mohammad, 2006). In such 
circumstances, healthy individuals may start drug use 
(Farhoudian et al., 2006; Somaini et al., 2012), and sev-
eral patients may relapse into their previous drug use and 
start their high-risk behaviors (Brandon, Vidrine, & Lit-
vin, 2007; Farhoudian et al., 2006; Rahimi Movaghar, 
et al., 2006). Anxiety, worry, depression, irritability, and 
anger in PWUD should be considered as a prodromal 
sign of lapse or relapse into a new episode of drug use. 
4.1. Psychological interventions
Psychosocial interventions are a vital element in the 
treatment of PWUD, especially in people using stimu-
lants and having mental problems (De Crescenzo et 
al., 2018). In this period, internet-based psychotherapy 
is highly recommended as a replacement. Internet con-
sultation, including phone calls, video chat, and short 
messages, have great potential to make psychological 
assessment and treatment more cost-effective. Comput-
er-assisted therapy appears to be as effective as a face-to-
face treatment for treating anxiety disorders and depres-
sion (Taylor & Luce, 2003). Although it requires some 
equipment and knowledge, it offers a good alternative 
for more isolated locations, which is relevant in this pan-
demic.
4.1.1. Cognitive Behavior Therapy (CBT)
Negative emotional states, including fear, anxiety, and 
boredom, as well as social withdrawal and or isolation, are 
the main emotions that patients will experience during the 
COVID-19 pandemic. CBT has been recognized as one of 
the most beneficial interventions for PWUD (Lee & Raw-
son, 2008). Stress reduction as a technique of CBT, either 
alone or in combination with pharmacotherapies, may 
prove beneficial in increasing quality of life and reducing 
cravings and promoting abstinence in clients seeking treat-
ment for SUD (Goeders, 2003). Clinicians should help their 
patients to identify, manage, and reduce their negative emo-
tional states associated with relapse and apply techniques 
of behavioral activation compatible with specific circum-
stances of each patient. Coping skills training and crisis in-
tervention are the most common types of CBT interventions 
to be recommended. 
4.1.2. Matrix model for ATS
Matrix model is a multi-element package of therapeutic 
strategies to produce an integrated outpatient treatment 
experience (Rawson & McCann, 2005; Rawson et al., 
1995). Treatment is delivered in an intensive outpatient 
program primarily in structured group sessions targeting 
the necessary skills. It is recommended that the meetings 
could be held individually instead of group format, hop-
ing to lessen the risk of COVID-19 infection. The rec-
ommended parts based on the manual (Services among 
Iranian people living with HIV and AIDS: A qualitative 
study, 2019) for the period of COVID19 pandemic in-
clude: 1. RP17: Taking care of yourself; 2. RP18: Emo-
tional triggers; 3. RP20: Recognizing stress; 4. RP22: 
Reducing stress; 5. RP24: Acceptance; 6. RP29: Coping 
with feelings and depression; 7. RP Elective C: Recre-
ational activities.
4.1.3. Contingency management
Incentive-based treatment approaches (i.e. Contin-
gency Management [CM]) are effective interventions 
in reducing addictive behaviors in PWUD (Ainscough, 
McNeill, Strang, Calder, & Brose, 2017; Benishek et al., 
2014; Lee & Rawson, 2008; Messina, Farabee,  & Raw-
son, 2003; Rawson et al., 2006). Evidence also supports 
the CM beneficial effect on the treatment of these indi-
viduals targeting infectious disease control (Herrmann , 
Matusiewicz,  Stitzer,  Higgins,  Sigmon,  & Heil, 2017). 
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To take advantage of CM in the prevention of COV-
ID-19, the desired behaviors (e.g. washing hands every 
hour, cleaning hands, etc.) and their scores or prizes (e.g. 
take-home doses) should be clearly defined and inserted 
into the list, just like other desired behaviors (e.g. nega-
tive urine test).
4.1.4. Enhancing social supports
Perceived social support from relatives and friends is a ma-
jor predictor for retention in treatment for PWUD (Radfar & 
Rawson, 2014; Shirinbayan, Rafiey, Vejdani Roshan, Naren-
jiha, & Farhoudian, 2010) and the main factor of psychologi-
cal resilience to disaster (Radfar, Nematollahi, & Arasteh, 2016; 
Rodriguez-Llanes, Vos,  & Guha-Sapir, 2013). Considering the 
importance of family support, clinicians are advised to engage 
family and care providers more than ever during the pandemic. 
Attracting other sources of social support such as guaranteed 
wages and an increase in social security payments will help the 
individual to pass this period with a better outcome. 
5. PWUD Specific Pathology Issues During 
Treatment for COVID-19 Infection
5.1. Respiratory illness
Opioids such as methadone are respiratory depressants, 
and tolerance develops very slowly and incompletely. 
When patients under MMT acquire COVID-19, they 
should be more closely monitored for both worsening 
respiratory functions and methadone toxicity. Abrupt 
cessation of methadone must be avoided because anxiety 
and agitation due to withdrawal syndrome may induce 
or worsen cardiorespiratory complications (Friedman, 
Kamel, Perez,  & Hamada, 2003; Kienbaum, Thurauf, 
Michel, Scherbaum, Gastpar, & Peters,, 1998). 
5.2. Renal insufficiency
The prevalence of kidney impairment in hospitalized 
COVID-19 patients is high, and renal insufficiency in-
creases the risk for in-hospital deaths (Cheng et al., 2020). 
Studies indicate that heroin users, especially PWID, 
suffer from nephropathy (Cunningham, Brentjens, 
Zielezny,  Andres, & Venuto, 1980; do Sameiro Faria, 
Sampaio,  Faria,  & Carvalho, 2003; May, Helderman, 
Eigenbrodt, & Silva, 1986). Other studies confirm that 
individuals using amphetamine (Ginsberg, Ertzman, 
& Schmidt-Nowara, 1970; Radfar & Rawson, 2014; 
Rifkin, 1977), cocaine (Merigian & Roberts, 1987; Nor-
ris et al., 2001; Sharff, 1984), alcohol (De Marchi, Cec-
chin, Basile, Bertotti,  Nardini,  & Bartoli, 1993; Perneg-
er, Whelton, Puddey, & Klag, 1999), and potent cannabis 
(Abodunde, Nakda, Nweke, & Veera, 2012; Gudsoorkar 
& Perez Jr, 2015) are more likely to suffer from renal 
failure. It might be logically concluded that people with 
a history of drug consumption are more prone to contract 
renal insufficiency when they are infected to COVID-19; 
however, there is not any revealing evidence so far. 
Evidence suggests that renal insufficiency does not af-
fect the metabolism of methadone in MMT patients 
(Murtagh, Chai, Donohoe, Edmonds, & Higginson, 
2007). Despite this issue, patients in acute renal fail-
ure due to COVID-19 should be monitored for signs of 
methadone toxicity because of other reasons for renal 
insufficiency. 
5.3. Cardiovascular disorders
Heart diseases increase the risk factors of death due to 
COVID-19 to 6% in affected individuals with hyperten-
sion, 7.3% in diabetics, and 10.5% in patients with other 
cardiovascular diseases (Murtagh et al., 2007).
Individuals with a history of alcohol or drug use are more 
likely to have cardiac pathology. Excessive alcohol con-
sumption (Fabrizio & Regan, 1994; Mirijello et al., 2017), 
amphetamine (Giv, 2017; O’neill et al., 2004), heroin 
(Routsi et al., 2007), and cocaine (Barton Duell, 1987) are 
all associated with the increased risk of cardiac pathology. 
5.4. Pain management
Contracting COVID-19 sometimes can result in mod-
erate to severe pain including myalgia, sore throat, and 
headache that requires pain management. It is recom-
mended that acute pain in PWID with COVID-19 is man-
aged in consultation with pain or addiction specialists.
People who use opioids regularly will require addi-
tional opioids for the management of pain (Athanasos, 
Smith, White, Somogyi,  Bochner,  & Ling,  2006; 
Doverty et al., 2001). Buprenorphine as a high-affinity 
partial agonist of mu-receptors has an analgesic effect 
in divided doses, but stops effecting other opioid anal-
gesics and hinders acute pain management in case of 
necessity (Harrington & Zaydfudim, 2010). In this case, 
buprenorphine can be ceased and opioid analgesics used 
or buprenorphine can be continued and non-opioid med-
ications such as clonidine, pregabalin/gabapentin and 
ketamine can be used (Goel et al., 2019).
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6. Treatment System Issues in a Time of COVID-19
Health services will need to rapidly adapt to the COV-
ID-19 situation. They will need to establish a mechanism 
of making decisions quickly and under stress, to identi-
fying the essential services to be continued, to develop 
new mechanisms of patient flow (including screening, 
batching and referral), to redistribute staff from non-es-
sential roles, and maintaining the continuity of essential 
supplies (Communications, 2020). To reduce the risk 
of transmission, it is generally recommended that non-
essential services close, or make their services available 
by telephone or on-line. When face-to-face services are 
required, some modifications may need to be made to the 
service system, for the identification of cases, the protec-
tion of staff, the reduction of transmission, and to ensure 
the continuity of essential services (Interim Guidline for 
Healthcare Facilities, 2020).
6.1. Case detection
When health services remain open in a pandemic, they 
should first invite all visitors to wash their hands before 
they touch anything. Then they should screen all new 
visitors with whatever SARS-CoV-2 screening mecha-
nism is appropriate for the local conditions. This may 
include a combination of temperature (where possible 
measured with a non-touch thermometer), clinical symp-
toms (cough, shortness of breath, sore throat), and epi-
demiological criteria (recent travel, contact with cases, 
health care worker). Where, possible, patients meeting 
the testing criteria should be tested on-site and then di-
rected to isolate themselves awaiting the results. For test-
ing and any subsequent clinical interaction, staff should 
wear Personal Protective Equipment (PPE) to protect 
themselves from transmission. If the client is coughing, 
it is preferable they should also wear a surgical mask 
(World Health Organization, 2020c). 
6.2. Prevention of transmission in health services
Transmission is through to be mostly via droplet spread 
when people who are infected sneeze, cough or talk. 
Staff and patients should wash their hands frequently and 
be careful what they touch. Surfaces should be cleaned 
after they have potentially contaminated. Depending on 
the availability of PPE and the risk in the local commu-
nity, it may be appropriate for staff to wear masks and 
gloves, or even gowns and eye protection. Patients with 
symptoms should wear a mask to prevent transmission 
through cough and sneezing. Patients can be divided into 
three risk groups, those with confirmed SARS-CoV-2 
virus, patients who meet criteria for testing awaiting 
test results, and other patients with differing levels of 
PPE depending on the availability of PPE. Preferably, 
patients with different risk levels should be treated in 
different parts of the health service. Staff and patients 
should keep a distance from each other (World Health 
Organization, 2020c).
6.3. Maintenance of essential services
In addition to providing OST, services should take the 
opportunity to encourage cessation of smoking by pre-
scription of NRT, and by the distribution of naloxone and 
overdose resuscitation. In preparation of staff members 
being sick or isolated awaiting test results, each staff 
member involved in OST treatment should have at least 
one other staff member who can continue their role if 
they are sick. Where possible, staff may separate into dif-
ferent teams who have even less contact, so that if one 
person is sick then the risk of all needing to isolate them-
selves is reduced (Guide on Business Continuity Plan-
ning for COVID-19, 7 February, 2020).  
7. Conclusions and Recommendations
PWUD are a marginalized hard-to-reach population 
living in crowded groups with lower access to health-
care. They usually suffer from poorer health, weaker 
immune function, chronic infections, as well as various 
issues with physical and psychiatric comorbidities. Con-
sequently, they have a higher risk of contracting CO-
VID-19 and its transmission and casualties. We believe 
that substance use and COVID-19 have a complicated 
relationship with each other. 
In summary, we suggest the following items:
Health authorities should develop and apply specific 
strategies for PWUD for early COVID-19 identification 
and patient isolation, interrupting transmission, provid-
ing appropriate care, attending medical issues, and mini-
mizing negative social impact.
Health authorities are responsible for providing ad-
equate healthcare for PWUDs. They may be required to 
repurpose and reorient health services through a business 
continuity team. This team implements evidence-based 
programs and makes decisions on how the organizations 
will continue to provide their services. Also, they make 
sure that all OST patients have adequate access to their 
opioid drugs.
Treatment sectors should provide essential require-
ments, as well as software and programs tailored to their 
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own clients’ needs. Staff may also teach the patients the 
hygiene rules, self-monitoring for signs of illness, and 
rapid reporting of the disease in case of occurrence.
A mechanism for frequently screening for signs and 
symptoms of infection should be established. Internet 
and mobile-based social media communications should 
be considered as the first-line approaches for education 
and appropriate interventions.
Opioid users face increased challenges; some concerns 
are about their take-home doses and repetitive visits 
that make it impossible for them to stay at home. This 
pandemic could be considered as an extraordinary cir-
cumstance; the clinicians should facilitate OST protocol 
for clinically stable patients and cancel all group-based 
interventions or therapies.
Healthcare workers in substance use treatment facilities 
are also facing a higher risk of infection, burnout, distress, 
psychiatric disorders, discrimination, and violence. The 
essential right for each service provider, no matter a peer 
group or professional service provider, is to be safe and 
secure, in both physical and mental health aspects.
Misinformation, social isolation, ensuing economic 
depression, and possible grief reactions may result in ex-
acerbation of public fear, panic, and distress that can be 
followed by lapse and relapse in ex-drug users.
Stress reduction, crisis interventions, coping skills 
training, motivational interviewing, and tailored and 
modified relapse prevention interventions, modification 
in contingency-based management for rewarding virus 
transmission preventive behaviours, attracting family 
support, managing patients’ vocational problems are the 
main helpful psychosocial interventions.
In this period, internet-based psychotherapy and phone 
counseling are highly recommended.
There are many medical considerations regarding 
PWUD that other physicians in charge of the manage-
ment of COVID-19 treatment should keep in their minds.
Clinicians should be careful in the differentiation be-
tween withdrawal signs and symptoms and those of CO-
VID-19 infection.
PWUD may have different clinical manifestations due 
to various etiologies. Healthcare providers should con-
sider different possible manifestations and, more impor-
tantly, avoid any type of medical stigma or discrimina-
tion against PWUD.
PWUD regularly self-medicate their physical and men-
tal problems with drugs, which may mask critical CO-
VID-19 symptoms.
A number of  drug-drug interactions between substance 
of use, addiction treatment medications, and COVID-19 
medications must be considered in terms of toxicity, 
withdrawal, and exacerbation of fatal side effects. 
There is also a possible overlap of pathological labo-
ratory results of the CBC and liver enzymes in PWUD 
and people with COVID-19 infection. Histories of renal 
failure, cardiovascular and metabolic diseases are more 
likely to emerge in PWUD that put them at higher risk 
of morbidity and mortality after contracting COVID-19
Pain management in PWUD, specifically opioid users 
and patients under OST, has some complexity, which 
calls for the involvement of joint expertise.
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